Industry Satellite Symposia
This symposium is for healthcare professionals only, it is not open to patients or members of the public.
Thursday 6 June 2024 13:00–14:00 BST Armadillo | Broadening treatment horizons for people with cystic fibrosis | |
|---|---|---|
Chaired by: Panellists: | ||
13:00–13:10 | Chair’s opening remarks: | Prof. Jane Davies |
13:10–13:30 | CFTR function restoration: | Prof. Marcus Mall |
13:30–13:45 | Rare mutations: | Prof. Pierre Regis Burgel |
13:45–13:55 | The remaining 7%: | Prof. Jane Davies |
13:55–14:00 | Chair’s closing remarks | Prof. Jane Davies |
There will be the opportunity for questions throughout the symposium.
Objectives:
• Discuss the importance of restoring CFTR function
• Describe the challenges in developing therapies for pwCF with rare mutations
• Highlight current and future therapy innovations to potentially reach all pwCF
Friday 7 June 2024 07:45 – 08:45 BST Hall 1 | What respiratory endpoints will be used to monitor CF patients with a CFTR-related disorder, specifically in older age groups, and what are the challenges? |
|---|---|
Gopal Allada MD Carl Mottram | Dr. Allada will review adult Cystic Fibrosis patients with a CFTR-related disorder and some of the challenges this diagnosis presents in late onset identification versus traditional “cystic fibrosis” patients which present with early onset of symptoms. Dr. Allada will present patient cases in an interactive session, with audience participation, to elicit discussion and gather clinical opinions on this unique patient population. He will also discuss a proposed follow up paradigm for these patients, highlighting information from the 2022 European Cystic Fibrosis Guidelines. These patients tend to have mild or even absent lung disease which may potentially be identified and followed with the measurement of Lung Clearance Index (LCI) and other lung function parameters. Professor Mottram will review recent literature related to LCI and spirometry testing including what challenges are present in performing these tests, new technical standards on testing, and current evidence related to home testing. |
This symposium is for healthcare professionals only, it is not open to patients or members of the public.
Friday 7 June 2024 13:00–14:00 BST Armadillo | Adapting to the new era for people with cystic fibrosis | |
|---|---|---|
Chaired by: Speakers: | ||
13:00–13:10 | Chair’s opening remarks: | Prof. Isabelle Fajac |
13:10–13:20 | Setting new standards for the paediatric CF population | Dr Florian Stehling |
13:20–13:35 | Impact of longer life: | Dr Eva Polverino |
13:35–13:45 | Ensuring all patients are on the journey: | Dr Andrea Gramegna |
13:45–14:00 | Q&A and Chair’s closing remarks | All speakers, |
Objectives:
• Provide an overview of the achievements of the CF clinical community, underscored by improvements to CFTR function
• Educate on the importance of treating early and the impact this has on CFTR function and extrapulmonary outcomes
• Highlight the need for alternative approaches to monitor clinical outcomes
• Raise awareness of the areas of unmet need in the care of pwCF, including the need for holistic care of ageing adults living with CF, and appropriate management for pwCF who are ineligible for current treatment options
The 45th European Cystic Fibrosis Conference has been assessed as compliant by EthicalMedTech.
Please view the assessment details: click here
MEDTECH EVENT
Thursday 6 June 2024 ePoster Corner B (M3) | Simeox therapy Clinical Evidence in Cystic Fibrosis |
|---|---|
• Simeox sputum clearance device: why and how Presenter: Laurent Morin, PhD, Medical Affairs Director (Physio-Assist) |